Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 studyPhilip A. Philip, Pascal Hammel, Edward Kim et al.|The Lancet. Gastroenterology & hepatology|2020Cited by 249
Efficacy and safety profile of nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic cancer treated to disease progression: a subanalysis from a phase 3 trial (MPACT)Arndt Vogel, Michael Ståhl, Alfredo Romano et al.|BMC Cancer|2016Cited by 36
Phase II LAPACT trial of <i>nab</i>-paclitaxel (<i>nab</i>-P) plus gemcitabine (G) for patients with locally advanced pancreatic cancer (LAPC).Pascal Hammel, Philip Agop Philip, Jill Lacy et al.|Journal of Clinical Oncology|2018Cited by 32